PRESS RELEASE published on 11/25/2025 at 07:00, 8 months 15 days ago Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination Relief Therapeutics and NeuroX reveal joint presentation and financial outlook in anticipation of business combination. Financial guidance includes revenue projections and EBITDA margin targets Business Combination Financial Outlook Relief Therapeutics Press Conference NeuroX
BRIEF published on 11/14/2025 at 18:25, 8 months 25 days ago Relief Therapeutics Shareholders Approve Merger with NeuroX Leadership Changes Shareholder Approval Capital Increase Relief Therapeutics NeuroX Merger
BRIEF published on 11/14/2025 at 18:25, 8 months 25 days ago Les actionnaires de Relief Therapeutics approuvent la fusion avec NeuroX Augmentation De Capital Approbation Des Actionnaires Thérapeutiques De Soulagement Fusion De NeuroX Changements De Leadership
PRESS RELEASE published on 11/14/2025 at 18:20, 8 months 25 days ago Relief Therapeutics Shareholders Approve Business Combination with NeuroX Relief Therapeutics shareholders approve business combination with NeuroX, creating a digital neurotherapeutics company. New board members elected. Business combination expected to close in December 2025 Shareholders Business Combination Relief Therapeutics NeuroX Digital Neurotherapeutics
BRIEF published on 10/29/2025 at 07:05, 9 months 12 days ago Relief Therapeutics Reports Positive Outcomes in RLF-OD032 Study FDA Approval RLF-OD032 Phenylketonuria Treatment Bioequivalence Study Sapropterin Dihydrochloride
BRIEF published on 10/29/2025 at 07:05, 9 months 12 days ago Relief Therapeutics annonce des résultats positifs dans l'étude RLF-OD032 Approbation De La FDA RLF-OD032 Traitement De La Phénylcétonurie Étude De Bioéquivalence Dichlorhydrate De Saproptérine
PRESS RELEASE published on 10/29/2025 at 07:00, 9 months 12 days ago Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 Relief Therapeutics announces positive results from pivotal bioequivalence study of RLF-OD032, demonstrating bioequivalence to KUVAN®, supporting NDA submission in early 2026 FDA Approval Relief Therapeutics RLF-OD032 Bioequivalence Study PKU Treatment
BRIEF published on 10/24/2025 at 07:04, 9 months 17 days ago Relief Therapeutics convoque une assemblée générale extraordinaire pour une fusion d'entreprises Assemblée Générale Extraordinaire THÉRAPEUTIQUE DE SECOURS Regroupement D'entreprises MindMaze Therapeutics Groupe NeuroX
BRIEF published on 10/24/2025 at 07:04, 9 months 17 days ago Relief Therapeutics Schedules Extraordinary General Meeting for Business Merger Business Combination Extraordinary General Meeting Relief Therapeutics MindMaze Therapeutics NeuroX Group
PRESS RELEASE published on 10/24/2025 at 06:59, 9 months 17 days ago Relief Therapeutics Convenes Extraordinary General Meeting Relief Therapeutics announces Extraordinary General Meeting to seek shareholder approval for business combination with NeuroX Group SA EGM Business Combination Extraordinary General Meeting Relief Therapeutics NeuroX Group SA
Published on 08/10/2026 at 14:30, 16 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 1 hour 16 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 1 hour 46 minutes ago Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada
Published on 08/10/2026 at 13:00, 1 hour 46 minutes ago Azarga Metals Mobilizes Drill Rig and Ancillary Equipment to Marg Project, Yukon
Published on 08/10/2026 at 13:00, 1 hour 46 minutes ago NioCorp to Host Webcast on Aug. 11 to Discuss Elk Creek Feasibility Study Results
Published on 08/10/2026 at 14:35, 11 minutes ago Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.81 Million Tokens, and Total Crypto and Total Cash Holdings of $11.6 Billion
Published on 08/10/2026 at 14:31, 15 minutes ago Heimo Scheuch decides to resign early as CEO of wienerberger for personal health reasons, Gerhard Hanke appointed Interim CEO
Published on 08/10/2026 at 14:30, 16 minutes ago Fitch Ratings upgrades outlook for Fresenius SE from stable to positive
Published on 08/10/2026 at 14:25, 21 minutes ago EQS-Adhoc: Ad hoc: Heimo Scheuch decides to resign early as CEO of wienerberger for personal health reasons, Gerhard Hanke appointed Interim CEO
Published on 08/10/2026 at 11:53, 2 hours 52 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:53, 2 hours 52 minutes ago GUILLEMOT CORPORATION |Informations relatives au nombre total de droits de vote et d’actions 31/07/2026
Published on 08/10/2026 at 11:36, 3 hours 9 minutes ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 11:36, 3 hours 9 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 3 au 7 août 2026
Published on 08/10/2026 at 09:47, 4 hours 59 minutes ago 260810 BENETEAU Transactions sur actions propres
